Improving the Recovery of rAAVs by Optimizing Cell Lysis Step

Want to enhance your viral vector manufacturing process and increase recovery of rAAVS? Learn how Avantor’s robust and efficient cell lysis can help.

Register Free: https://www.pharmtech.com/pt_w/optimizing-cell-lysis

Event Overview:

Many gene therapies and viral vaccines rely on recombinant adeno-associated virus (rAAV) to deliver DNA to cells. DNA packaging and subsequent purification of the rAAV particles can be challenging, as certain viral vector serotypes are not easily released from the cell. Thus, the cell membrane must be ruptured to release the viral vector particles, where they can be purified from the resulting solution. Mechanical methods can be harsh on the particles. Therefore, and alternatively, an effective cell lysis solution can be used for this initial step in the harvest of rAAV.

Key Learning Objectives

• The benefits of using a novel cell lysis solution that can rapidly rupture cell membranes across a wide range of operating conditions and provide protection against sheer induced damage that may occur during subsequent manufacturing steps.
• Why this cell lysis agent is compatible with other traditional DNA impurity removal agents that are used during viral vector purification.
• How the resulting rAAVs retain their ability to infect cells.
• Why this novel cell lysis agent can be used to enhance the overall viral vector manufacturing process by providing robust and efficient cell lysis that can increase the recovery of rAAVs.

Who Should Attend:

• Process Development lead
• MSAT engineers
• Process Development engineers
• Director of Manufacturing Operations
• Strategic Sourcing/Procurement

Speaker:

Courtney O’Dell
Senior Scientist
Avantor

Courtney O'Dell has been a senior scientist with Avantor’s Technology and Innovation group in Bridgewater, NJ, for the past 5 years. She has been supporting biopharma applications for upstream cell culture processing, specifically focused on working on projects related to cell lysis for viral vector release, optimizing viral vector titer production in suspension cells and looking at spent media analysis. In addition to the upstream workflow, she has been using her previous background in monoclonal antibody formulation development to investigate novel protein additives to enhance stability and reduce viscosity of monoclonal antibody formulations. Prior to her position with Avantor, Courtney spent 11 years working in solution formulation development of monoclonal antibodies at ImClone Systems and then Eli Lilly & Co., focusing on stability, structural characterization, and use-time compatibility studies for parenteral drug delivery.

Register Free: https://www.pharmtech.com/pt_w/optimizing-cell-lysis